PuraPharm Corporation Limited (“PuraPharm”) has announced the appointment of Mr. Dong Zimeng as a non-executive director, effective 30 October 2025.

Mr. Dong, aged 40, has 17 years of experience in capital market investments, mergers and acquisitions, fund management, and corporate operations. Since September 2024, he has served as managing partner and responsible officer of Providence Capital Group Limited, focusing on overseeing operations, setting corporate strategies, and managing investments. Prior to that role, he was president of Shenzhen Capital International Co., Ltd. from August 2021 to September 2024, and previously held positions as president and chairman within Co-High Asset Management.

Mr. Dong holds a Master of Science in Applied Bioengineering and a Bachelor of Engineering in Electronic Information Engineering from the University of Warwick, earned in 2008 and 2006, respectively. He was nominated by Providence Discovery Fund in accordance with a subscription agreement dated 25 July 2025.

Under his letter of appointment, Mr. Dong’s initial one-year term will renew automatically unless terminated by either party, and he will be subject to shareholder re-election at the next annual general meeting, as well as periodic rotation. His annual remuneration is HK$200,000, payable quarterly.

According to the announcement, Mr. Dong has no shareholding in the company, no relationships with other directors or major shareholders, and holds no other positions within PuraPharm or its subsidiaries. The board expressed a warm welcome to Mr. Dong in joining PuraPharm’s leadership team.